IRVINE, CA--(Marketwire - Nov 8, 2012) - BIOLASE, Inc. (NASDAQ: [ BIOL ]), the world's leading dental laser manufacturer and distributor, ranked 25^th in the Orange County Business Journal's 2012 Fastest-Growing Public Companies list. Rankings are based on percentage revenue growth for the 12-month period ended June 30, 2012 as compared with the 12-month period ended June 30, 2010. BIOLASE grew 58.5% during this period.

Federico Pignatelli, Chairman and CEO, said, "We are pleased to have been recognized by the Orange County Business Journal for our strong growth over the past two years, reflecting the positive impact of our many efforts. This includes re-establishing our direct sales force in North America and the launch of our revolutionary WaterLase iPlus all-tissue laser. Our 2012 third quarter results show continued growth in our core WaterLase technology, as well as in our imaging products. We expect this trend to continue with the launch of our EPIC 10 diode soft tissue laser, for which we have already generated a healthy backlog after recent receipt of regulatory clearance."

Orange County Business JournalSelection and Qualifications
Each year, the Orange County Business Journal provides a ranking of the fastest growing Orange County-based companies that trade on U.S. exchanges. Rankings for 2012 are determined based on the percentage of trailing 12-month revenue growth from June 30, 2010, to June 30, 2012.

Companies must have recorded sales of at least $300,000 for the 12 months ended June 30, 2010. Furthermore, sales for the 12 months ended June 30, 2012, must represent at least 13% revenue growth as compared with the two-years prior period. Based on these criteria, 69 companies were included on the 2012 Fastest-Growing Public Companies list. The Orange County Business Journal compiled the financial data with the help of Los Angeles-based investment bank B. Riley & Co., along with regulatory filings and other sources.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets [ dental lasers ] and also distributes and markets dental [ imaging equipment ]; products that are focused on technologies that advance the practice of dentistry and [ medicine ] at the molecular level. The Company's laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal [ products ] are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 20,600 lasers. Other products under development address ophthalmology and other medical and consumer markets.

WaterLase^®, iPlus™, and EPIC™ are trademarks of BIOLASE, Inc.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at [ www.biolase.com ], Facebook at [ www.facebook.com/biolaseinc ], Twitter at [ twitter.com/biolaseinc ], and YouTube at [ www.youtube.com/biolasevideos ].

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives, product introductions and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.